Regeneron Pharmaceuticals (REGN) Other Non Operating Income (2013 - 2026)

Regeneron Pharmaceuticals has reported Other Non Operating Income for 14 years, with the latest figure at $201.2 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non Operating Income fell 37.52% year-over-year to $201.2 million; the trailing twelve-month figure through Mar 2026 stood at $1.6 billion (up 31.21% YoY), and the FY2025 full-year result was $1.7 billion, up 100.92% from the prior year.
• Other Non Operating Income for Q1 2026 stood at $201.2 million, up from $176.0 million in the prior quarter.
• The five-year high for Other Non Operating Income was $755.8 million in Q3 2025, with the low at -$183.8 million in Q1 2022.
• Average Other Non Operating Income over 5 years is $185.1 million, with a median of $193.0 million recorded in 2023.
• Peak annual rise in Other Non Operating Income reached 1937.8% in 2022, while the deepest fall reached 218.66% in 2022.
• Tracing REGN's Other Non Operating Income over 5 years: stood at $195.3 million in 2022, then decreased by 1.18% to $193.0 million in 2023, then slumped by 111.19% to -$21.6 million in 2024, then jumped by 914.81% to $176.0 million in 2025, then grew by 14.32% to $201.2 million in 2026.
• The last three Other Non Operating Income figures came in at $201.2 million (Q1 2026), $176.0 million (Q4 2025), and $755.8 million (Q3 2025), per Business Quant data.

Peer Comparison